SOURCE: Equity News Circuit

Equity News Circuit

February 26, 2013 08:45 ET

Free Research Reports on APPY, HTZ, OBCI and SCLN Issued by the Bedford Report

Note to Editors: The Following Is an Investment Opinion Being Issued by the EQUITY NEWS CIRCUIT

NEW YORK, NY--(Marketwire - Feb 26, 2013) - The Bedford Report has released new equity reports today. As a leading provider of free in depth reports and timely market updates, Bedford is an essential resource for hundreds of thousands of investors across the country.

Venaxis Inc. (NASDAQ: APPY) shares surged 12.15 percent on more than twelve times the average daily volume Monday to close at $2.40 a share. Analysts at Canaccord have upgraded the company's rating from "hold" to "buy" and have raised its price target to $7.00 citing.

Find out more about Venaxis including full access to the free equity report at: www.BedfordReport.com/APPY

Hertz Global Holdings, Inc. (NYSE: HTZ) shares surged sharply in early trading Monday before closing at $19.04 a share on over 18 million shares traded Monday. The company reported record worldwide revenues of $2.3 billion in the fourth quarter, an increase of 15.1 percent year-over-year.

Find out more about Hertz Global Holdings including full access to the free equity report at: www.BedfordReport.com/HTZ

Ocean Bio-Chem, Inc. (NASDAQ: OBCI) shares gained 25.8 percent on nearly ten times the average daily volume Monday to close at $2.88 a share. The company announced that the U.S. Environmental Protection Agency has approved Xtrem-A-Cide P for use as a sanitizer, virucide, tuberculocide, fungicide, algaecide, slimicide and deodorizer.

Find out more about Ocean Bio-Chem including full access to the free equity report at: www.BedfordReport.com/OBCI

SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) shares declined 8.7 percent on nearly three times the average daily volume Monday to close at $4.40 a share. The company announced it would restate financial statements for the first, second and third quarters of 2012 and the second and third quarters of 2011 and for the year ended December 31, 2011.

Find out more about SciClone Pharmaceuticals including full access to the free equity report at: www.BedfordReport.com/SCLN

Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein.

A third party, Providence Media Strategies LLC has paid Equity News Circuit five hundred dollars for the publication of this news release. Neither Equity News Circuit, nor the hiring party, has a financial relationship with any company whose stock is mentioned in this release. Neither Equity News Circuit nor the hiring party are a registered investment advisor, and nothing in this report is intended as a solicitation to buy or sell any security.

Contact Information